Zentalis Pharmaceuticals paid its 5 named executives $7.0M in total in FY2025 (Dec). CEO Julie Eastland was paid $1.3M of that.
Pay$100 in the stock at the end of FY23 → $9
Pay of each named executive
Andrea PaulFormer Chief Legal Officer and Corporate Secretary
| FY2025 (Dec) | Not disclosed | ||||||
| FY2022 (Dec) | Not disclosed |
2 years
Julie EastlandPresident and Chief Executive Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) |
2 years
Mark Lackner, Ph.D.Former Chief Scientific Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) |
2 years
Ingmar Bruns, M.D.Chief Medical Officer
| FY2025 (Dec) |
1 year
James BucherChief Legal Officer and Corporate Secretary
| FY2025 (Dec) |
1 year
CEO pay against the pay peers
In FY2023 (Dec), the median CEO pay of the 15 peers with pay on file was $7.9M. CEO pay of Zentalis Pharmaceuticals for that year is not on file.
- 1Relay Therapeutics
- 2Allogene Therapeutics
- 3CRISPR Therapeutics AG
- 4Arcus Biosciences
- 5Kymera Therapeutics
- 6Cytokinetics
- 7Celldex Therapeutics
- 8Denali Therapeutics
- 9Arvinas
- 10Beam Therapeutics
- 11Kura Oncology
- 12C4 Therapeutics
- 13Fate Therapeutics
- 14Nektar Therapeutics
- 15Lyell Immunopharma
- 16Zentalis PharmaceuticalsThis companyNot disclosed
- 17Day One Biopharmaceuticals, Inc.Not disclosed
- 18ErascaNot disclosed
- 19ImmunoGen, Inc.Not disclosed
- 20Merus N.V.Not disclosed
- 21Mirati Therapeutics, Inc.Not disclosed
- 22Sana BiotechnologyNot disclosed
- 23Springworks Therapeutics, Inc.Not disclosed
- 24TG TherapeuticsNot disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.